Together, these data demonstrate that GR antagonism can suppress key proproliferative targets such as CCND1 and TGFα leading to antitumor effects in a subset of FOXA1-dependent NSCLC. The gene discussed is NR3C1; the disease is non-small cell lung carcinoma.